The GMZ2 Consortium is an integrated project for “Fostering research capacity, networking and project management through phase I-IIb clinical trials of candidate malaria vaccine GMZ2” involving seven partners. The partnership of international institutions are working to support further development of GMZ2 (GLURP + MSP3 hybrid) malaria vaccine candidate, which is currently in phase Ib clinical trials in Gabon. The partners are the African Malaria Network Trust (AMANET), Statens Serum Institute (SSI), the Medical Research Unit at Albert Schweitzer Hospital (MRU-ASH) in Gabon, the Medical Research Council (MRC) Laboratories in The Gambia, the Centre National de Recherche et de Formation sur le Paludisme (CNRFP) in Burkina Faso, Makerere University in Uganda and the University of Tübingen, Germany. The GMZ2 Consortium invites applications for long term training to further strengthen the African trial sites by consolidating their leadership capabilities in implementation of clinical trials. The call is open to applicants from the four African sites in the consortium.